{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:43:49Z","timestamp":1781613829252,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jdiacomp.2023.108414","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:38:22Z","timestamp":1675427902000},"page":"108414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fatty acid binding protein 1 (FABP1) and fatty acid binding protein 2 (FABP2) as a link between diabetic nephropathy and subclinical atherosclerosis in children and adolescents with type 1 diabetes"],"prefix":"10.1016","volume":"37","author":[{"given":"Mohamed","family":"Abo El-Asrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Abdel Rahman","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Mohamed","family":"Elnhrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha Adel","family":"Thabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108414_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJNRD.S40172","article-title":"Diabetic nephropathy - complications and treatment","volume":"7","author":"Lim","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14007","article-title":"An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines","volume":"22","author":"Selby","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0015","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1021\/acs.biochem.9b00625","article-title":"Identification of fatty acid binding protein 5 inhibitors through similarity-based screening","volume":"58","author":"Zhou","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0020","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.7150\/ijms.49078","article-title":"FABP1 and FABP2 as markers of diabetic nephropathy","volume":"17","author":"Tsai","year":"2020","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0025","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s12098-016-2144-9","article-title":"Diagnostic value of intestinal fattyacid-binding protein in necrotizing enterocolitis: a systematic review and meta-analysis","volume":"83","author":"Yang","year":"2016","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cca.2011.09.018","article-title":"Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis","volume":"413","author":"Mou","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0035","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2337\/dc12-1868","article-title":"Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes","volume":"36","author":"Panduru","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jiac.2014.10.017","article-title":"A newly developed kit for the measurement of urinary liver-type fatty acidbinding protein as a biomarker for acute kidney injury in patients with critical care","volume":"21","author":"Sato","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jss.2018.04.057","article-title":"Intestinal fatty acid-binding protein levels in patients with chronic renal failure","volume":"230","author":"Okada","year":"2018","journal-title":"J Surg Res"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/pedi.12773","article-title":"ISPAD clinical practice consensus guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents","volume":"19","author":"Mayer-Davis","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0055","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2337\/diacare.24.9.1560","article-title":"Does microalbuminuria predict diabetic nephropathy?","volume":"24","author":"Tabaei","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0060","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2337\/diacare.27.2007.S79","article-title":"American Diabetes Association. Nephropathy in diabetes","volume":"27","author":"Molitch","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0065","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/pedi.12742","article-title":"ISPAD clinical practice consensus guidelines 2018: microvascular and macrovascular complications in children and adolescents","volume":"19","author":"Donaghue","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/adc.41.220.613","article-title":"Standards from birth to maturity for height, weight, height velocity and weight velocity: british children, 1965.II","volume":"41","author":"Tanner","year":"1966","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdiacomp.2005.11.002","article-title":"Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes","volume":"21","author":"Weintrob","year":"2007","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0080","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0085","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2014.12.029","article-title":"Intima media thickness measurement in children: a statement from the Association for European Paediatric Cardiology (AEPC) Working Group on Cardiovascular Prevention endorsed by the Association for European Paediatric Cardiology","volume":"238","author":"Dalla Pozza","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0090","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/13510002.2017.1301624","article-title":"Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in \u03b2-thalassemia major","volume":"22","author":"Adly","year":"2017","journal-title":"Redox Rep"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s13104-018-3670-5","article-title":"Diabetic nephropathy and hypertension in diabetes patients of sub-saharan countries: a systematic review and meta-analysis","volume":"11","author":"Wagnew","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1900\/RDS.2015.12.110","article-title":"Diabetic nephropathy: new risk factors and improvements in diagnosis","volume":"12","author":"Tziomalos","year":"2015","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0105","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.2337\/diacare.28.8.2038","article-title":"Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy","volume":"28","author":"Suzuki","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0110","article-title":"Assessment of urinary liver-type fatty acid binding protein (LFABP) levels in type 2 diabetes mellitus patients with nephropathy","volume":"13","author":"Kare","year":"2019","journal-title":"JCDR"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5604\/17322693.966983","article-title":"The clinical significance of fatty acid binding proteins","volume":"65","author":"Choroma\u0144ska","year":"2011","journal-title":"Postepy Hig Med Dosw"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0120","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/ki.2014.301","article-title":"Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury","volume":"87","author":"Parr","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.ki.5002721","article-title":"Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery","volume":"73","author":"Portilla","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12986-016-0089-7","article-title":"The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity","volume":"13","author":"Lau","year":"2016","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/bjs.9331","article-title":"Diagnostic performance of plasma biomarkers in patients with acute intestinal ischaemia","volume":"101","author":"Matsumoto","year":"2014","journal-title":"Br J Surg"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jss.2012.10.008","article-title":"Detection of patients at high risk for non-occlusive mesenteric ischemia in hemodialysis","volume":"180","author":"Quiroga","year":"2013","journal-title":"J Surg Res"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00270-014-0844-y","article-title":"A scoring-system for angiographic findings in nonocclusive mesenteric ischemia (NOMI): correlation with clinical risk factors and its predictive value","volume":"37","author":"Minko","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0150","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1172\/JCI117778","article-title":"An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance","volume":"95","author":"Bar","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00535-011-0373-2","article-title":"Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study","volume":"46","author":"Kanda","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0160","article-title":"Intestinal fatty acid-binding protein, a biomarker of intestinal barrier dysfunction, increases with the progression of type 2 diabetes","volume":"9","author":"Wang","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0165","first-page":"965","article-title":"FABP2 and PPAR-Y genes as risk factors for dyslipidemia in type 2 diabetes mellitus in residents of United Arab Emirates","volume":"6","author":"Ganah","year":"2015","journal-title":"IJBPR"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/ndt\/gfs350","article-title":"Dysregulation of hepatic fatty acid metabolism in chronic kidney disease","volume":"28","author":"Jin","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0175","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/HYPERTENSIONAHA.112.199828","article-title":"Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury","volume":"60","author":"Ichikawa","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0180","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.21608\/ejhm.2021.170511","article-title":"Relationship between serum adipocyte fatty acid binding protein and atherosclerosis in type 2 diabetes patients","volume":"83","author":"Allam","year":"2021","journal-title":"EJHM"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCRESAHA.116.308334","article-title":"Atherosclerosis: successes, surprises, and future challenges","volume":"118","author":"Libby","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jdiacomp.2014.01.011","article-title":"Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness","volume":"28","author":"Adly","year":"2014","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jdiacomp.2017.10.014","article-title":"Urinary miRNA-377 and miRNA-216a as biomarkers of nephropathy and subclinical atherosclerotic risk in pediatric patients with type 1 diabetes","volume":"32","author":"El Samahy","year":"2018","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0200","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/pedi.12686","article-title":"Osteopontin as a marker of vasculopathy in pediatric patients with type 1 diabetes mellitus: relation to vascular structure","volume":"19","author":"Abo El-Asrar","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MCA.0b013e32833db539","article-title":"The role of heart-type fatty acid-binding protein in predicting properties of coronary atherosclerosis in patients with acute coronary syndrome","volume":"21","author":"Kalay","year":"2010","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0210","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1753-0407.12549","article-title":"Serum adipocyte fatty acid-binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus","volume":"10","author":"Ding","year":"2018","journal-title":"J Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-13-81","article-title":"The value of apolipoprotein B\/Apolipoprotein A1 ratio for metabolic syndrome diagnosis in a chinese population: a cross-sectional study","volume":"13","author":"Jing","year":"2014","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jdiacomp.2023.108414_bb0220","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1111\/jcmm.15173","article-title":"Intestinal fatty acid-binding protein mediates atherosclerotic progress through increasing intestinal inflammation and permeability","volume":"24","author":"Zhang","year":"2020","journal-title":"J Cell Mol Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:16:00Z","timestamp":1761005760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1056872723000120"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108414","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid binding protein 1 (FABP1) and fatty acid binding protein 2 (FABP2) as a link between diabetic nephropathy and subclinical atherosclerosis in children and adolescents with type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108414"}}